chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. aiming to be a healthcare group with a global presence, fosun pharma, established in shanghai in 1994, has built its core business around innovative drug r&d and manufacturing.
innovation for health — the fourth hongqiao international health technology innovation forum held in shanghai
on november 6, 2021, as a parallel supporting event of the 4th china international import expo (ciie), the 4th hongqiao international health technology innovation forum with the theme of "innovation for good health" was successfully held. this forum was sponsored by the international health exchange and cooperation center nhc prc (ihecc) and china pharmaceutical innovation and research development association,
2021 csco | henlius publishes newest phase ii clinical data of novel anti-pd-1 mab serplulimab for treatment of advanced cervical cancer
in this meeting, henlius releases phase 2 study results of serplulimab (hlx10, novel anti-pd-1 antibody), in patients with advanced cervical cancer in an oral presentation.
2021 csco | henlius publishes phase iii clinical data of bevacizumab biosimilar hlx04 for treatment of metastatic colorectal cancer
in this meeting, henlius releases phase 3 study results of hlx04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.
the global development center of fosun pharma is responsible for managing the clinical development of new drugs for fosun pharma and its subsidiaries.
it is mainly engaged in the organization and coordination of clinical trials of drugs, cro management, protocol design for clinical trials, project implementation, data management, statistical analysis and preparation of final reports. in addition, it is responsible for providing suggestions on the strategic planning of products from the clinical point of view, thus providing medical professional guarantee for project approval, innovator drug development and drug evaluation. its business covers the planning and implementation of clinical trials of traditional chinese medicine, chemicals and biologics at various phases.
- after years of continuous development and accumulative innovation, the global development center sets its foot in china, the united states and europe. it has a systematic and perfect whole-process r&d platform from the discovery of innovator drugs to clinical study and to post-marketing reevaluation.
- under the product development principles of "global linkage and integrated innovation", the company has established its r&d centers in china, the united states and europe to achieve outstanding synergistic advantages. these three r&d centers work closely together to ensure a cost-effective and productive r&d process.